JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M-001
universal influenza vaccine candidate, reported today it will
present this week at the 18th MIXiii-BIOMED Conference and
Exhibition in Tel Aviv,
Israel.
Dr. Tamar Ben-Yedidia, BiondVax's
Chief Scientific Officer, will provide an overview of the Company's
achievements and plans, including the ongoing pivotal, clinical
efficacy, Phase 3 trial.
Details of Dr. Ben-Yedidia's presentation:
Update of the Pivotal, Clinical Efficacy, Phase 3 trial of
BiondVax's M-001 Universal Influenza Vaccine
Date: Wednesday, May 15,
2019
Time: 16:40 - 16:55
Location: Hall B, David InterContinental Hotel,
Tel Aviv, Israel
About BiondVax
BiondVax (NASDAQ: BVXV) is a
Phase 3 clinical stage biopharmaceutical company developing a
universal flu vaccine. The vaccine candidate, called M-001, is
designed to provide multi-strain and multi-season protection
against current and future, seasonal and pandemic influenza.
BiondVax's proprietary technology utilizes a unique combination of
conserved and common influenza virus peptides intended to stimulate
both arms of the immune system for a cross-protecting and
long-lasting effect. In a total of 6 completed Phase 1/2 and Phase
2 clinical trials, covering 698 participants, the vaccine has been
shown to be safe, well-tolerated, and immunogenic. The ongoing
pivotal Phase 3 clinical trial aims to assess safety and
effectiveness of M-001 in reducing flu illness and severity. Please
visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements reflect the management's current views with respect to
certain current and future events and are subject to various risks,
uncertainties and assumptions that could cause the results to
differ materially from those expected by the management of BiondVax
Pharmaceuticals Ltd. Risks and uncertainties include, but are
not limited to, the prosecution and outcome of the ongoing Phase 2
and Phase 3 trials and any subsequent trials; timing of
receipt of regulatory approval of the new manufacturing facility;
ability to demonstrate the efficacy and safety of the vaccine; the
timing of clinical trials and marketing approvals; the risk that
drug development involves a lengthy and expensive process with
uncertain outcome; the ability of the Company to maintain, preserve
and defend its intellectual property and patents granted; whether
our vaccine candidate will successfully advance through the
clinical trial process on a timely basis, or at all, and receive
approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; the
adequacy of available cash resources and the ability to raise
capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our Annual Report on Form 20-F for the
year ended December 31, 2018 filed
with the U.S. Securities and Exchange Commission, or SEC, which is
available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC. We undertake no obligation
to revise or update any forward-looking statement for any
reason.
Contact Details
Joshua E.
Phillipson
+972-8-930-2529
j.phillipson@biondvax.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biondvax-to-provide-update-of-m-001-universal-flu-vaccine-pivotal-phase-3-clinical-trial-at-18th-mixiii-biomed-conference-300848716.html
SOURCE BiondVax Pharmaceuticals Ltd.